Tie2-Expressing Monocytes for Angiogenesis Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with excessive angiogenesis or insufficient blood vessel growth are inadequate, and there is a need for methods to monitor angiogenesis in patients undergoing treatment.
Innovation Solution
Identification and characterization of human Tie2-expressing monocytes (TEMs) with distinct surface markers, which can promote or inhibit angiogenesis, and their use in therapies, diagnostics, and gene delivery for regulating angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional angiogenesis therapies are used, then blood vessel growth is stimulated, but treatment effectiveness is insufficient and lacks targeted monitoring
Solution Approach 1:
The patent uses Tie2-expressing monocytes as intermediary cells that naturally target sites of angiogenesis. These monocytes serve as living vectors that deliver therapeutic genes specifically to areas needing treatment, eliminating the need for complex external delivery systems while improving treatment reliability through targeted action
Solution Approach 2:
The patent employs the body's own Tie2-expressing monocytes to perform the therapeutic function. By genetically modifying these endogenous cells, they autonomously navigate to angiogenic sites and deliver treatment, eliminating the need for complex external delivery mechanisms and enabling self-directed targeted therapy
2Measurement precision
If angiogenesis is monitored in patients, then treatment monitoring capability is improved, but diagnostic complexity increases
Solution Approach 1:
The patent uses luciferase reporter genes that produce bioluminescent signals in Tie2-expressing monocytes. This allows non-invasive optical monitoring of angiogenesis in real-time through simple imaging, providing precise measurement without complex diagnostic equipment
Solution Approach 2:
The patent incorporates reporter genes that provide real-time feedback on angiogenesis activity and gene delivery effectiveness. This continuous monitoring capability allows treatment optimization based on actual biological responses, improving measurement precision through simple readout mechanisms
3Adaptability or versatility
If Tie2-expressing monocytes are used for targeted therapy, then treatment specificity is improved, but cell isolation and characterization complexity increases
Solution Approach 1:
The patent uses Tie2 as a natural intermediary marker that specifically identifies monocytes involved in angiogenesis. This endogenous marker eliminates the need for complex exogenous labeling systems while providing high treatment specificity through natural biological targeting
Solution Approach 2:
The patent exploits the specific surface marker expression profile of Tie2-expressing monocytes (CD14+, CD16+, Tie2+) as a parameter change that enables their identification and isolation. This natural phenotypic distinction simplifies cell sorting compared to creating artificial markers, reducing isolation complexity while maintaining high targeting capability
Data Source
AI summary
The present invention relates to human and mouse monocyte cells expressing Tie2 and CD14 or CD16 and their use in methods for regulating angiogenesis and vascular integrity, such as methods of inducing angiogenesis, promoting vessel growth or stabilization, treating pathological disorders, inhibiting angiogenesis, and diagnosing or monitoring a pathological disorder.